Lionel Carnot, MS, MBA, is a Managing Director of Bay City Capital, joining the firm in 2005 after having been extensively involved in the firm’s activities as part of The Pritzker Organization since 2000. Mr. Carnot is based in Bay City Capital’s office in Basel, Switzerland, where he manages the firm’s European activities, enhancing the firm’s visibility into the European health care innovation industry and the global life sciences community. He contributes significant pharmaceutical and diagnostics transactional and strategic expertise to Bay City Capital’s investment portfolio.
Mr. Carnot is currently a member of the board of directors of Interleukin Genetics, Merus B.V., and Madrigal Pharmaceuticals. He is a former member of the board of several companies, including Reliant Pharmaceuticals, which was sold to GlaxoSmithKline in 2007 marking the single largest all-cash transaction for a venture-backed biotech company at that time.
Prior to The Pritzker Organization, Mr. Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly as well as several sales and marketing positions at Sanofi-Aventis. Mr. Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services. Mr. Carnot holds an MBA with Distinction from INSEAD and an MS with honors in Molecular Biology from the University of Geneva.